In Vivo and In Vitro Diagnostics Converge: Siemens buys DPC
Executive Summary
Why would imaging giant Siemens buy traditional in vitro diagnostics firm Diagnostic Products for $1.86 billion? Siemens has a mature imaging business, so the high growth opportunities in diagnostics, with their recurring revenue streams from consumables, look attractive. But more than that, it's becoming apparent that on the molecular level, in vivo imaging and in vitro diagnostics are converging.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports